|Quantity Discounts||1 - 9999|
|1 - 9999|
|1 - 9999|
And now, nearly a year later, Congress and public interest groups are putting the pressure on the agency to crack down on noncompliance and invoke its new power.
Understand these new rules, have best practices and strategies in place to comply with them and avoid potentially devastating penalties — including huge fines, bad publicity and the possibility of congressional scrutiny.
Gain the knowledge you need to allay your fears and concerns …
In a 90-minute Encore presentation, Arnold & Porter’s Vernessa Thomas Pollard and Dan Kracov will detail what you need to do to comply with the new laws to avoid being penalized, trends in the FDA’s use of civil penalties and what to expect in the near future.
Sign up your entire team to listen in and discover:
Register now and find out what you need to know about the FDA’s new civil penalties and how to avoid them. Plus, you’ll get an opportunity to ask your toughest questions during the Q&A session.
This presentation is a must for positions in the drug, device and biologic industry, including:
Vernessa Thomas Pollard is counsel in Arnold & Porter's FDA and healthcare practice group, where she focuses her practice on a variety of regulatory, policy and litigation matters. Prior to joining Arnold & Porter, Vernessa spent six years as Associate Chief Counsel for Enforcement in the Office of Chief Counsel at the FDA, where she represented the agency in a variety of enforcement actions and defensive litigation matters. During her tenure at the FDA, she advised agency clients and DOJ lawyers on a wide range of compliance and regulatory matters involving drugs, dietary supplements, cosmetics, medical devices, pharmacy compounding, product labeling, GMP requirements, disclosure of records under the Freedom of Information Act (FOIA), and responding to Congressional inquiries.
Dan Kracov heads the pharmaceutical and medical device practice at the law firm Arnold & Porter. He assists clients — including start-up companies, trade associations and large manufacturing companies — in negotiating the challenges relating to the development, approval and marketing of drugs, biologics and medical devices. His experience in the FDA’s strategic advice and crisis management won him a spot on the Fall 2005 Legal Times list of "Leading Lawyers in Food & Drug Law." Dan regularly handles product- and compliance-related investigations, the development of regulatory corporate compliance programs, and due diligence in financings, mergers and acquisitions. He has widely recognized experience in biomedical-product-related public policy matters, including Congressional investigations and FDA-related legislative strategies.
|Date:||Dec. 8–26, 2008|
|Location:||Your office or conference room (no need to travel!)|
Gather your team for maximum benefit! Your investment is for one dial-in.
We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.
Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600
Registrations may not be cancelled. Please contact customer service to make any substitutions.
Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing